ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

In Brief: Congressional Action Imminent On Cancer Ac Renewal, Hew Money Bills; Veto Threatened

September 8, 1978

Turmoil in Texas: DePinho Recommended AVEO Stock on CNBC Six Days After FDA Said New Trial Was Needed

May 10, 2013

NCI Cooperative Group, Cancer Center Trials Listed

September 26, 2008

FDA Advisors Debate Ban, Black Box And Status Quo of Power Morcellators

July 25, 2014

In Brief: Chabner Says He ”Has No Intention Of Leaving NCI; “Yarbro Named Clinical Indicators Chairman

September 2, 1988

Centers Can Collaborate Well with Industry, Albert LoBuglio Says

May 7, 1999